A little over a year after landing its flagship approval in chronic hives, Novartis’ oral BTK inhibitor Rhapsido is expanding ...
After facing a setback in Germany late last year, Merck & Co.’s European marketing plans for its below-the-skin Keytruda SC are growing more complicated. | After facing a setback in Germany late last ...
The National Fragility Index, launched by the API Innovation Center, warns that more than 550 million prescriptions filled in the U.S. in 2023 were for drugs ranked as having high or severe ...
The successes of the GLP-1 class for chronic weight management “introduced consumer overlay over a historically physician-driven therapeutic area,” Pothier explained, noting that despite the potency ...
NBA Champion Karl-Anthony Towns knows both ball and COVID-19. | New York Knicks champ Karl-Anthony Towns is sharing his personal experience with COVID to encourage others to talk with their doctors ...
The possibility of psychedelic therapies for PTSD or treatment-resistant depression in the U.S. has never been greater. But even as the industry inches closer to an FDA go-ahead, the realities of ...
Catalent is vying for a stronger foothold in next-gen drug development, and it's betting on developer's need for speed. | ...
The bright, sunny shots of Noom’s chief wellness ambassador Rebel Wilson seen in the debut of the digital health company’s ...
As competition in both the HIV treatment and prevention fields continues to mount, GSK’s ViiV Healthcare is looking to expand ...
AbbVie and Genmab are touting a much-anticipated first-line win for | Epkinly plus R-CHOP cut the risk of progression or death by 51% compared with R-CHOP alone in newly diagnosed DLBCL, setting up a ...
Through its pledge, BD will invest $19 billion in the U.S. over the span of “several years,” with the outlay taking the form of capital, operational and supply chain investments, the company said in ...
Already boasting a positive recommendation overseas, Novo’s hemophilia A newcomer Frehemgo will have to wait a while longer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results